Octopus Ventures, a venture capital investor specializing in health, money, and deep tech, led a $50m Series B round in Automata, an automation company helping life sciences rapidly innovate, diagnose and discover at scale, with participation from Hummingbird, Latitude Ventures, ABB Technology Ventures, Isomer Capital, and In-Q-Tel. "I’m really excited at how this funding will take us on the next stage of our successful journey. At Automata we have always believed in the power of automation to support a variety of uses, especially when deployed at scale. We are thrilled to see our users adopt automation at a scale that transforms their ability to deliver more innovation in the life sciences and ultimately accelerates their pursuit of progress. For far too long scientists and clinicians have been having to work with overly complex lab solutions whereby the equipment and software are disjointed and difficult to orchestrate. Solutions are also often too rigid and inappropriate for labs with small geographic footprints. Our next generation technology solves this," Mostafa ElSayed, Automata CEO.